MX2016000724A - Compuestos de reserva de los receptores activados del proliferador de peroxisoma (ppar) para el tratamiento de enfermedades metabolicas. - Google Patents
Compuestos de reserva de los receptores activados del proliferador de peroxisoma (ppar) para el tratamiento de enfermedades metabolicas.Info
- Publication number
- MX2016000724A MX2016000724A MX2016000724A MX2016000724A MX2016000724A MX 2016000724 A MX2016000724 A MX 2016000724A MX 2016000724 A MX2016000724 A MX 2016000724A MX 2016000724 A MX2016000724 A MX 2016000724A MX 2016000724 A MX2016000724 A MX 2016000724A
- Authority
- MX
- Mexico
- Prior art keywords
- treatment
- ppar
- disease
- metabolic diseases
- sparing compounds
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/63—One oxygen atom
- C07D213/68—One oxygen atom attached in position 4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/075—Ethers or acetals
- A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4402—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C259/00—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups
- C07C259/04—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids
- C07C259/06—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids having carbon atoms of hydroxamic groups bound to hydrogen atoms or to acyclic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
- C07C309/63—Esters of sulfonic acids
- C07C309/64—Esters of sulfonic acids having sulfur atoms of esterified sulfo groups bound to acyclic carbon atoms
- C07C309/65—Esters of sulfonic acids having sulfur atoms of esterified sulfo groups bound to acyclic carbon atoms of a saturated carbon skeleton
- C07C309/66—Methanesulfonates
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C317/00—Sulfones; Sulfoxides
- C07C317/16—Sulfones; Sulfoxides having sulfone or sulfoxide groups and singly-bound oxygen atoms bound to the same carbon skeleton
- C07C317/22—Sulfones; Sulfoxides having sulfone or sulfoxide groups and singly-bound oxygen atoms bound to the same carbon skeleton with sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/28—Radicals substituted by singly-bound oxygen or sulphur atoms
- C07D213/30—Oxygen atoms
Abstract
La presente invención se refiere a compuestos de hidroxamato y composiciones farmacéuticas que son útiles para tratar y/o prevenir enfermedades metabólicas mediadas por la inflamación tales como diabetes, obesidad, hipertensión, dislipidemia, un trastorno neurodegenerativo (por ejemplo, enfermedad de Alzheimer, enfermedad de Parkinson o enfermedad de Huntington), cualquier combinación de las mismas. Sin embargo, la presente invención también proporciona métodos de tratamiento para estas enfermedades o trastornos.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361856850P | 2013-07-22 | 2013-07-22 | |
PCT/US2014/047411 WO2015013187A1 (en) | 2013-07-22 | 2014-07-21 | Ppar-sparing compounds for the treatment of metabolic diseases |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2016000724A true MX2016000724A (es) | 2016-04-13 |
Family
ID=51300860
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2016000724A MX2016000724A (es) | 2013-07-22 | 2014-07-21 | Compuestos de reserva de los receptores activados del proliferador de peroxisoma (ppar) para el tratamiento de enfermedades metabolicas. |
Country Status (14)
Country | Link |
---|---|
US (1) | US9562012B2 (es) |
EP (1) | EP3024816B1 (es) |
JP (1) | JP6498195B2 (es) |
KR (1) | KR102349803B1 (es) |
CN (2) | CN105764884B (es) |
AU (1) | AU2014293405B2 (es) |
CA (1) | CA2918376C (es) |
DK (1) | DK3024816T3 (es) |
ES (1) | ES2813363T3 (es) |
HU (1) | HUE050549T2 (es) |
IL (1) | IL243637B (es) |
MX (1) | MX2016000724A (es) |
RU (1) | RU2687490C2 (es) |
WO (1) | WO2015013187A1 (es) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3758494A4 (en) | 2018-03-02 | 2022-03-16 | Oregon Health & Science University | AMIDPRODRUGS OF SMALL MOLECULES NUCLEAR RECEPTOR MODULATORS |
CN113423684A (zh) | 2018-12-12 | 2021-09-21 | 速通医疗公司 | 新型拟甲状腺素药 |
CA3130371A1 (en) | 2019-03-01 | 2020-09-10 | Autobahn Therapeutics, Inc. | Novel thyromimetics |
GB202210503D0 (en) | 2022-07-18 | 2022-08-31 | Univ Court Univ Of Glasgow | Materials and methods for treatment of chronic myeloid leukemia (CML) |
Family Cites Families (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5304121A (en) | 1990-12-28 | 1994-04-19 | Boston Scientific Corporation | Drug delivery system making use of a hydrogel polymer coating |
JPH0556057A (ja) * | 1991-08-28 | 1993-03-05 | Matsushita Electric Ind Co Ltd | ループネツトワークシステム |
US5716981A (en) | 1993-07-19 | 1998-02-10 | Angiogenesis Technologies, Inc. | Anti-angiogenic compositions and methods of use |
US6099562A (en) | 1996-06-13 | 2000-08-08 | Schneider (Usa) Inc. | Drug coating with topcoat |
JP2002515742A (ja) | 1996-05-02 | 2002-05-28 | ファルマシア・アンド・アップジョン・カンパニー | Cdc25b様活性を有する触媒性高分子 |
JPH11158144A (ja) * | 1997-09-19 | 1999-06-15 | Ss Pharmaceut Co Ltd | α−置換フェニルプロピオン酸誘導体及びこれを含有する医薬 |
DE69815008T2 (de) * | 1997-09-19 | 2004-04-01 | Ssp Co., Ltd. | Alfa-substituierte Phenylpropionsäurederivate und diese enthaltende Arzneimittel |
SE9801992D0 (sv) * | 1998-06-04 | 1998-06-04 | Astra Ab | New 3-aryl-2-hydroxypropionic acid derivative I |
MA26634A1 (fr) * | 1998-06-04 | 2004-12-20 | Astra Ab | Nouveaux derives de l'acide 3-aryl propionique et analogues |
TWI311133B (en) * | 2001-04-20 | 2009-06-21 | Eisai R&D Man Co Ltd | Carboxylic acid derivativeand the salt thereof |
WO2006029575A1 (en) * | 2004-09-17 | 2006-03-23 | Institute Of Mataria Medica, Chinese Academy Of Medical Sciences | NOVEL α-ALKYLOXY PROPIONIC ACIDS, THEIR PREPARATION METHODS, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USES |
PL2001468T3 (pl) | 2006-03-16 | 2013-03-29 | Metabolic Solutions Dev Co Llc | Analogi tiazolidynodionu |
PL2001469T3 (pl) | 2006-03-16 | 2012-10-31 | Metabolic Solutions Dev Co Llc | Analogi tiazolidynodionu |
US8304441B2 (en) | 2007-09-14 | 2012-11-06 | Metabolic Solutions Development Company, Llc | Thiazolidinedione analogues for the treatment of metabolic diseases |
AU2008301905B2 (en) | 2007-09-14 | 2013-06-27 | Cirius Therapeutics, Inc. | Thiazolidinedione analogues for the treatment of hypertension |
ES2617704T3 (es) * | 2009-12-15 | 2017-06-19 | Octeta Therapeutics, Llc | Tiazolidindionas ahorradoras de PPAR y combinaciones para el tratamiento de enfermedades neurodegenerativas |
WO2011084453A1 (en) | 2009-12-15 | 2011-07-14 | Metabolic Solutions Development Company | Ppar-sparing thiazolidinedione salts for the treatment of metabolic diseases |
WO2012177956A1 (en) * | 2011-06-23 | 2012-12-27 | Metabolic Solutions Development Comapny, Llc | Ppar-sparing compounds for use in the treatment of diabetes and other metabolic diseases |
-
2014
- 2014-07-21 EP EP14750080.5A patent/EP3024816B1/en active Active
- 2014-07-21 RU RU2016102080A patent/RU2687490C2/ru active
- 2014-07-21 DK DK14750080.5T patent/DK3024816T3/da active
- 2014-07-21 KR KR1020167004024A patent/KR102349803B1/ko active IP Right Grant
- 2014-07-21 CA CA2918376A patent/CA2918376C/en active Active
- 2014-07-21 JP JP2016529814A patent/JP6498195B2/ja active Active
- 2014-07-21 ES ES14750080T patent/ES2813363T3/es active Active
- 2014-07-21 AU AU2014293405A patent/AU2014293405B2/en active Active
- 2014-07-21 US US14/906,686 patent/US9562012B2/en active Active
- 2014-07-21 CN CN201480052078.6A patent/CN105764884B/zh active Active
- 2014-07-21 HU HUE14750080A patent/HUE050549T2/hu unknown
- 2014-07-21 CN CN201811086509.7A patent/CN109400502A/zh active Pending
- 2014-07-21 WO PCT/US2014/047411 patent/WO2015013187A1/en active Application Filing
- 2014-07-21 MX MX2016000724A patent/MX2016000724A/es unknown
-
2016
- 2016-01-17 IL IL243637A patent/IL243637B/en active IP Right Grant
Also Published As
Publication number | Publication date |
---|---|
KR102349803B1 (ko) | 2022-01-12 |
IL243637B (en) | 2020-01-30 |
CN109400502A (zh) | 2019-03-01 |
AU2014293405B2 (en) | 2018-11-22 |
CA2918376C (en) | 2023-05-02 |
CA2918376A1 (en) | 2015-01-29 |
JP2016531111A (ja) | 2016-10-06 |
KR20160033741A (ko) | 2016-03-28 |
RU2016102080A (ru) | 2017-08-28 |
RU2016102080A3 (es) | 2018-05-22 |
DK3024816T3 (da) | 2020-08-31 |
ES2813363T3 (es) | 2021-03-23 |
EP3024816A1 (en) | 2016-06-01 |
EP3024816B1 (en) | 2020-06-03 |
US20160152570A1 (en) | 2016-06-02 |
RU2687490C2 (ru) | 2019-05-14 |
US9562012B2 (en) | 2017-02-07 |
WO2015013187A1 (en) | 2015-01-29 |
AU2014293405A1 (en) | 2016-02-04 |
CN105764884A (zh) | 2016-07-13 |
HUE050549T2 (hu) | 2020-12-28 |
IL243637A0 (en) | 2016-02-29 |
CN105764884B (zh) | 2019-01-18 |
WO2015013187A8 (en) | 2015-08-20 |
JP6498195B2 (ja) | 2019-04-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2021004492A (es) | Composiciones para el tratamiento de trastornos del snc. | |
PH12016501600A1 (en) | 2-amino-3, 5, 5-trifluoro-3, 4, 5, 6-tetrahydropyridines as bace1 inhibitors for treatment of alzheimer's disease | |
MX2015007479A (es) | Tiazolidindionas ahorradoras de receptores activados proliferadores de peroxisoma (ppar) y combinaciones para el tratamiento de enfermedades neurodegenerativas. | |
PH12017501669A1 (en) | Alpha-cinnamide compounds and compositions as hdac8 inhibitors | |
TN2017000134A1 (en) | 2-amino-3,5-difluoro-3,6-dimethyl-6-phenyl-3,4,5,6-tetrahydropyridines as bace1 inhibitors for treating alzheimer's disease | |
WO2015108490A3 (en) | Heteroaryl alkyne derivatives and uses thereof | |
PH12017500841B1 (en) | 2-amino-6-(difluoromethyl)- 5,5-difluoro-6-phenyl-3,4,5,6-tetrahydropyridines as bace1 inhibitors | |
MX2017005282A (es) | Nuevos compuestos como inhibidores de la cinasa inductora de nf-kb (nik). | |
PH12019500196A1 (en) | Compounds and compositions and uses thereof | |
CR20160394A (es) | Heteroaril amidas como inhibidores de agregación de proteína | |
MX2019004859A (es) | Tratamientos de combinacion que comprenden la administracion de imidazopirazinonas. | |
MX2016013029A (es) | Compuestos de indanona sustituidos como modulares de gpr119 para el tratamiento de diabetes, obesidad, dislipidemia y trastornos relacionados. | |
MX2018002446A (es) | Compuestos heterociclicos fusionados como moduladores s1p. | |
NZ709399A (en) | Method of treatment of hypoxia inducible factor (hif)-related conditions | |
ZA202002993B (en) | Compounds for the treatment of neuromuscular disorders | |
MY184878A (en) | Compositions and methods for treating neurodegenerative diseases | |
PH12019500198A1 (en) | Compounds and compositions and uses thereof | |
MX2017009849A (es) | Composiciones de profármaco de monometilfumarato. | |
MX2016000724A (es) | Compuestos de reserva de los receptores activados del proliferador de peroxisoma (ppar) para el tratamiento de enfermedades metabolicas. | |
MX2019001634A (es) | Compuestos amidas, composiciones farmacéuticas de estos y métodos para utilizarlos. | |
EA201790315A1 (ru) | Модуляторы x-рецепторов печени | |
MX2018001592A (es) | Composiciones y metodos para el tratamiento y la prevencion de trastornos neurodegenerativos. | |
NZ702239A (en) | Heteroaryl compounds and methods of use thereof | |
MX2017006692A (es) | Trastornos neurodegenerativos. | |
MX2016008968A (es) | Compuestos organicos. |